Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736406 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
A Phase 1 study of Primary Glioblastoma, sponsored by Hemerion Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT05736406: Recruiting Phase 1 study of Primary Glioblastoma, sponsored by Hemerion Therapeutics.
NCT05736406 is a Phase 1 study of Primary Glioblastoma that is actively recruiting participants, run by Hemerion Therapeutics. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736406, a Phase 1 study of Primary Glioblastoma, is actively recruiting participants, sponsored by Hemerion Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study . The study will utilize an independent Data and Safety Monitoring Board (iDSMB) that will review safety data to allow dose escalation.
Primary Outcome
Evaluation of Dose Limiting Toxicities (DLT) to define MDT
Conditions Studied
Interventions
- COMBINATION_PRODUCT 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2
- COMBINATION_PRODUCT 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Study Locations (2)
Pennsylvania
- UPMC Hillman Cancer center - Pittsburgh
Other
- CHU De Lille, Hôpital Roger Salengro - Lille
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT05736406 shows while recruiting
NCT05736406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Primary Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2 is the first listed.
NCT05736406 reports a single indexed study location in Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT05736406 about?
NCT05736406 is a clinical study titled "A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma". The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treatment will be carried...
What is the current status of trial NCT05736406?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-02-20. Estimated completion is 2026-07.
What conditions does trial NCT05736406 study?
This clinical trial studies the following conditions: Primary Glioblastoma.
What interventions are being tested in trial NCT05736406?
The interventions under investigation include: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2 (COMBINATION_PRODUCT), 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05736406?
This trial is sponsored by Hemerion Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736406 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05736406's enrollment target sits among peer trials
12 1853rd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI